Merck to Acquire Terns Pharmaceuticals for $6.7 B, Accelerating M&A Ahead of Keytruda Patent Expiry

Why It Matters

Merck’s $6.7 billion acquisition of Terns signals a decisive shift from reliance on a single blockbuster drug to a multi‑product growth model. By expanding its oncology pipeline, Merck can offer a broader suite of therapies to hospitals and health systems, strengthening its B2B relationships and reducing vulnerability to biosimilar competition. The deal also illustrates how large pharmaceutical firms are using M&A to accelerate innovation cycles, a trend that reshapes the B2B market for drug distribution, pricing negotiations, and collaborative research. As Merck integrates Terns’ assets, partners across the supply chain will need to adapt to new product launches, potentially altering procurement strategies and contract structures in the oncology space.

Key Takeaways

• Merck agreed to acquire Terns Pharmaceuticals for $53 per share, valuing the deal at $6.7 billion.
• The acquisition adds TERN‑701, an oral BCR::ABL1 inhibitor in Phase I/II trials for chronic myeloid leukemia.
• Merck’s prior M&A activity includes $9.2 billion for Cidara Therapeutics and ~ $10 billion for Verona Pharma.
• Keytruda, Merck’s flagship PD‑1 inhibitor, contributes over 50% of pharmaceutical sales and faces biosimilar competition after 2028.
• The deal is expected to close in Q2 2026, pending customary closing conditions.

Pulse Analysis

Merck’s recent acquisition spree reflects a broader industry pivot toward pipeline diversification as a hedge against patent cliffs. Historically, pharma giants have relied on a few blockbuster drugs to drive revenue, but the accelerating entry of biosimilars and the high cost of internal R&D have made external sourcing more attractive. By targeting late‑stage assets like TERN‑701, Merck reduces development risk while gaining immediate market credibility through FDA designations.

From a B2B perspective, the expanded portfolio enhances Merck’s leverage in negotiations with health systems that increasingly demand value‑based contracts tied to clinical outcomes across multiple indications. A diversified drug slate enables Merck to bundle therapies, negotiate better rebate structures, and offer integrated solutions that align with the procurement strategies of large hospital networks. This could translate into higher market share in oncology, a segment where payer pressure is intensifying.

Looking ahead, Merck’s ability to integrate acquired assets quickly will be critical. Successful integration can accelerate time‑to‑market for TERN‑701 and future candidates, reinforcing Merck’s reputation as a reliable partner for B2B customers. Conversely, integration missteps could delay product launches, eroding the intended offset to Keytruda’s revenue decline. Investors and industry observers will watch Merck’s next moves—whether further acquisitions, strategic alliances, or internal development— to gauge how effectively the company can sustain growth in a post‑Keytruda era.